Part, Chapter, Paragraph
1 II, 5. 5. 2| people over 85. A DELPHI consensus method was used. This is
2 II, 5. 5. 2| prevalence of dementia: a Delphi consensus study. The Lancet, Vol.
3 II, 5. 5. 3| MS;~· It signposts core consensus documents and materials
4 II, 5. 5. 3| the EU Member States.~ ~EU Consensus documents and reference
5 II, 5. 5. 3| Immunomodulatory Therapy of MS Consensus Paper~· Current therapeutic
6 II, 5. 5. 3| multiple sclerosis therapy consensus group (MSTCG) critically
7 II, 5. 5. 3| Symptomatic Therapies Consensus Paper based on the German
8 II, 5. 5. 3| developed and published consensus guidelines based on the
9 II, 5. 5. 3| of MS neurologists. The Consensus paper includes treatment
10 II, 5. 5. 3| policy developments and consensus papers in the field. In
11 II, 5. 5. 3| Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German
12 II, 5. 5. 3| Multiple sclerosis therapy consensus group) and Rieckmann P (
13 II, 5. 5. 3| Multiple sclerosis therapy consensus group) (2007): “Escalating
14 II, 5. 5. 3| Immunomodulatory Therapy of MS Consensus Paper , Revised version
15 II, 5. 5. 3| Multiple Sclerosis Therapy Consensus Group~PML~Progressive Multifocal
16 II, 5. 9. 5| indicators; and agree on and gain consensus with local physician champions
17 II, 9. 1. 1| indicators using a DELPHI consensus process with scientific
18 II, 9. 1. 1| evidence, as well as the consensus of epidemiologists, clinicians
19 II, 9. 2. 2| national systems, hence consensus of topics and definitions
20 II, 9. 2. 2| immensely complicated to reach a consensus on common instruments for
21 II, 9. 3. 1| sequelae. There is a lack of consensus as to whether changes in
22 II, 9. 3. 1| immensely complicated to reach a consensus on common instruments for
23 II, 9. 3. 1| varies widely. There is consensus about the marked temporal
24 II, 9. 3. 1| male sexual function.’ (NIH consensus development panel, 1992).
25 II, 9. 3. 1| Whilst there is little consensus over the actual numbers
26 II, 9. 3. 1| Currently, there is no universal consensus on the hormonal and clinical
27 II, 9. 3. 1| Disorders, 71(1-3):1-9.~ ~NIH Consensus Development Program (1992)
28 II, 9. 3. 1| National Institutes of Health Consensus Development Conference Statement.
29 II, 9. 3. 1| Available from: http://consensus.nih.gov/1992/1992Impotence091html.
30 II, 9. 3. 2| developed since it requires a consensus on conditions to include
31 III, 10. 2. 1| measures. There is a broad consensus on the effectiveness of
32 III, 10. 2. 1| society. There is broad consensus on the effectiveness of
33 III, 10. 2. 1| Europe (1999): Gothenburg Consensus Paper. Health impact assessment:
34 III, 10. 4. 2| PCBs~ ~There is general consensus on the science of dioxin
35 III, 10. 4. 2| EFSA. There was general consensus that a risk-benefit analysis
36 III, 10. 4. 5| community autonomy and build consensus.~ ~Since the cost of hazardous
37 III, 10. 5. 3| enterprises. The scientific consensus is that preventive measures
38 IV, 11. 1. 3| has brought to a growing consensus towards the concept that
39 IV, 11. 1. 3| population health outcomes; a consensus supported and in part driven
40 IV, 11. 1. 5| systematic framework, or even consensus, on how to define quality
41 IV, 11. 1. 5| countries was developed, and consensus recommendations of an international
42 IV, 11. 5. 1| diseases, establishing a consensus about common basic guidelines
43 IV, 11. 5. 3| Figure 11.16 shows, there is consensus in the use of a number of
44 IV, 11. 5. 6| to contribute to create a consensus on European common standards
45 IV, 11. 5. 6| organ donation – a European consensus document~1997Recom 16 on
46 IV, 12. 7 | to the development of a consensus on the approaches to assess
47 IV, 13. 3 | at European level, of a consensus methodological approach
